## Louisiana Medicaid GLP-1 Receptor Agonists (GLP-1s) Criteria for Quantity Limit or Maximum Dose Override

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request authorization to override quantity or maximum dose limits that apply to GLP-1s.

Additional Point-of-Sale edits may apply.

## **Approval Criteria**

- **ONE** of the following is required and is **stated on the request**:
  - The recipient has had a positive response to the requested therapy without evidence of adverse effects; **AND** 
    - The recipient had a partial but inadequate response to the requested medication at a lower dosage; AND
    - The recipient is currently taking the requested dosage; **OR**
    - The recipient has taken the requested dosage in the past; **OR**
  - The recipient had a *partial but inadequate response* to the requested medication *at a lower dosage or quantity* **AND ALL** of the following:
    - Medication non-adherence was ruled out as a reason for the inadequate response; AND
    - The recipient *tolerated* the medication at *the lower dosage*; **AND**
    - There was *no evidence of adverse effects* at the lower quantity or dose; **AND**
    - The medication quantity or dose, as requested, is necessary for this patient; **OR**
  - The recipient has not previously used this medication; however, the prescriber is citing references supporting the quantity limit or maximum dose exception with this request (for example, a peer-reviewed journal article demonstrating the safety and efficacy of the requested quantity or dose for the indication); AND
- The requested quantity or dose is supported in the accepted medical compendia for the recipient's diagnosis; AND
- The medication dose, as requested, is medically necessary for this patient.

## **Duration of approval: 6 months**

## References

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; https://www.clinicalkey.com/pharmacology/

DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: A Pathophysiologic Approach, 10e New York, NY: McGraw-Hill; <a href="https://accesspharmacy.mhmedical.com/book.aspx?bookid=1861">https://accesspharmacy.mhmedical.com/book.aspx?bookid=1861</a>

| Revision / Date              | <b>Implementation Date</b> |
|------------------------------|----------------------------|
| Policy Created / August 2024 |                            |